Indoco Remedies - India Business Revival To Trigger Price-To-Earnings Multiple Expansion In FY22: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Indoco Remedies Ltd.’s Q3 FY21 revenue were in-line with our estimate based on growth led by export formulations while Ebitdam beat of 90 basis points due to operating leverage through cost saving program.
We maintain our positive outlook on the company and believe -
1. Medical representative productivity would improve to Rs 3 lakhs/month (from Rs 2.5 lakh/month) with similar headcounts of field force,
2. India formulations growth to return to 10- 12% from FY22,
3. U.S. launch of ophthalmic and oral abbreviated new drug applications in partnerships and
4. lower remediation cost as regulatory issue is resolved.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.